BR0014312A - Combinação de loteprednol e anti-histaminas - Google Patents

Combinação de loteprednol e anti-histaminas

Info

Publication number
BR0014312A
BR0014312A BR0014312-0A BR0014312A BR0014312A BR 0014312 A BR0014312 A BR 0014312A BR 0014312 A BR0014312 A BR 0014312A BR 0014312 A BR0014312 A BR 0014312A
Authority
BR
Brazil
Prior art keywords
loteprednol
combination
antihistamines
antihistamins
rhinoconjunctivitis
Prior art date
Application number
BR0014312-0A
Other languages
English (en)
Other versions
BR0014312B1 (pt
Inventor
Istvan Szelenyi
Degenhard Marx
Sabine Heer
Juergen Engel
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of BR0014312A publication Critical patent/BR0014312A/pt
Publication of BR0014312B1 publication Critical patent/BR0014312B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçãO DE LOTEPREDNOL E ANTIHISTAMINAS". A presente invenção refere-se a uma nova combinação de um esteróide mole, em particular loteprednol, e de pelo menos uma antihistamina, tal como, por exemplo, azelastina e/ou levocabastina, para administração simultânea, seq³encial ou separada no tratamento local de alergias e distúrbios das vias áreas, por exemplo de rinite alérgica (rinoconjuntivite).
BRPI0014312-0A 1999-09-30 2000-09-26 composição farmacêutica contendo uma combinação farmacêutica compreendendo loteprednol e azelastina, medicamento e seu processo de produção, e uso da referida combinação. BR0014312B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947234A DE19947234A1 (de) 1999-09-30 1999-09-30 Neue Kombination von Loteprednol und Antihistaminika
PCT/EP2000/009391 WO2001022955A2 (de) 1999-09-30 2000-09-26 Neue kombination von loteprednol und antihistaminika

Publications (2)

Publication Number Publication Date
BR0014312A true BR0014312A (pt) 2002-05-21
BR0014312B1 BR0014312B1 (pt) 2012-09-04

Family

ID=7924100

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0014312-0A BR0014312B1 (pt) 1999-09-30 2000-09-26 composição farmacêutica contendo uma combinação farmacêutica compreendendo loteprednol e azelastina, medicamento e seu processo de produção, e uso da referida combinação.

Country Status (19)

Country Link
US (1) US7022687B1 (pt)
EP (1) EP1216046B1 (pt)
JP (2) JP5524438B2 (pt)
AR (1) AR025923A1 (pt)
AT (1) ATE241988T1 (pt)
AU (1) AU7907300A (pt)
BR (1) BR0014312B1 (pt)
CA (1) CA2387398C (pt)
CZ (1) CZ295090B6 (pt)
DE (2) DE19947234A1 (pt)
DK (1) DK1216046T3 (pt)
EE (1) EE04997B1 (pt)
ES (1) ES2199868T3 (pt)
HU (1) HU229606B1 (pt)
MX (1) MXPA02003174A (pt)
PL (1) PL196843B1 (pt)
PT (1) PT1216046E (pt)
TW (1) TWI224968B (pt)
WO (1) WO2001022955A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258175T3 (es) * 2001-12-05 2006-08-16 Alcon, Inc. Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis.
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
PL373433A1 (en) * 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
BR0316203A (pt) * 2002-11-12 2005-10-04 Alcon Inc Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
PT1572217E (pt) 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
US8371292B2 (en) 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
MXPA06010849A (es) * 2004-03-25 2007-03-08 Bausch & Lomb Uso de loteprednol etabonato para el tratamiento del ojo seco.
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
DK2486942T3 (en) 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
WO2012094283A2 (en) * 2011-01-04 2012-07-12 Ista Pharmaceuticals, Inc. Bepotastine compositions
EP2854781A4 (en) * 2012-05-25 2016-04-13 Xlear Inc XYLITOL-BASED ANTIMUKOSAL COMPOSITIONS AND ASSOCIATED METHODS AND COMPOSITIONS
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
JP7791119B2 (ja) * 2020-06-15 2025-12-23 アルケム・ラボラトリーズ・リミテッド アルカフタジンとコルチコステロイドの組み合わせ
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
WO1997001337A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
JPH11511758A (ja) * 1996-06-04 1999-10-12 ザ、プロクター、エンド、ギャンブル、カンパニー 鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬
JP4453987B2 (ja) * 1997-01-16 2010-04-21 千寿製薬株式会社 点鼻用水性懸濁液

Also Published As

Publication number Publication date
JP2003510275A (ja) 2003-03-18
MXPA02003174A (es) 2003-08-20
DE19947234A1 (de) 2001-04-05
WO2001022955A3 (de) 2001-05-17
CZ20021014A3 (cs) 2002-06-12
TWI224968B (en) 2004-12-11
AU7907300A (en) 2001-04-30
EE04997B1 (et) 2008-04-15
EP1216046B1 (de) 2003-06-04
JP2012001558A (ja) 2012-01-05
CZ295090B6 (cs) 2005-05-18
HUP0202862A3 (en) 2003-10-28
DK1216046T3 (da) 2003-09-29
HUP0202862A2 (hu) 2003-01-28
WO2001022955A2 (de) 2001-04-05
EE200200146A (et) 2003-04-15
BR0014312B1 (pt) 2012-09-04
CA2387398C (en) 2009-05-12
EP1216046A2 (de) 2002-06-26
ATE241988T1 (de) 2003-06-15
PL353486A1 (en) 2003-11-17
JP5524438B2 (ja) 2014-06-18
HU229606B1 (en) 2014-02-28
US7022687B1 (en) 2006-04-04
DE50002478D1 (de) 2003-07-10
PT1216046E (pt) 2003-10-31
AR025923A1 (es) 2002-12-18
CA2387398A1 (en) 2002-03-28
PL196843B1 (pl) 2008-02-29
ES2199868T3 (es) 2004-03-01

Similar Documents

Publication Publication Date Title
CA2387398A1 (en) Novel combination of loteprednol and antihistamines
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
BR0014912A (pt) Tratamento de distúrbios do sono usando desloratadina
WO2004019884A3 (en) Agents and methods for enhancing bone formation
ATE311148T1 (de) Chirurgische vorrichtungen
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
NO20003546L (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
NO20033446D0 (no) Medikament for behandling av osteonekrose og for pleie av personer med risiko for å utvikle osteonekrose
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
SE0104423D0 (sv) Pregnane steroids and their use in the treatment of CNS disorders
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
WO2003082196A3 (en) Combination therapy using trefoil peptides
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
GB0020504D0 (en) Therapeutic method
NO20024735L (no) Anvendelse av fulvestrant for behandling av resistent brystkreft
BG105471A (bg) Метод за предотвратяване или забавяне на необходимостта от катетър-основан на реваскуларизация
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
UA86802C2 (ru) Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
NO990450L (no) Behandling av sinnslidelser
BR0014374A (pt) Combinação de loteprednol e agonistas do adrenorreceptor beta dois
BR0113646A (pt) Tratamento de distúrbios inflamatórios

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VIATRIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050037237/RJ DE 17/05/2005.

B25D Requested change of name of applicant approved

Owner name: MEDA PHARMA GMBH AND CO. KG (DE)

Free format text: ALTERADO DE: VIATRIS GMBH AND CO. KG

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/09/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.